Slide 1: FY 2022 Results
FY 2022 RESULTS March 27, 2023
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to comments of any person presenting it. This document, taken together you solely for your information and may not be reproduced, in whole or in
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which DiaSorin operates and the beliefs and assumptions of the management of DiaSorin. In addition, the management of DiaS
Slide 4: Financial Highlights
FINANCIAL HIGHLIGHTS DiaSorin
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Change Data in €/mln FY’22 @ current @ CER Revenues 1,361 +10.0% +2.4% Immunodiagnostics ex-COVID 680 +8.4% +3.3% Molecular Diagnostics ex-COVID 223 +65.2% +48.8% Licensed Technologies 214 +120.6% +98.1% COVID 244 -35.5% -40.1% Adjusted EBITDA* 514 -5.3% -11.0% Adjusted EBITDA M
Slide 6: Key Facts: Immunodiagnostics
KEY FACTS PRODUCT & BUSINESS DEVELOPMENT IMMUNODIAGNOSTICS • FDA 510 (k) clearance of the LIAISON® MeMed BV® test, developed following the licensing agreement signed with MeMed. The test is the first high throughput blood test to differentiate between viral and bacterial infections. • Validation of
Slide 7: Key Facts: Molecular Diagnostics
KEY FACTS PRODUCT & BUSINESS DEVELOPMENT MOLECULAR DIAGNOSTICS • New Simplexa™ SARS-CoV-2 Variants Direct Assay (Research Use Only) for the detection of mutations associated with the new COVID Omicron variant. • CE Marking of ARIES® Flu A/B & RSV+SARS-CoV-2 Assay for the detection of the 4 most comm
Slide 8: Key Facts: Licensed Technologies
KEY FACTS PRODUCT & BUSINESS DEVELOPMENT LICENSED TECHNOLOGIES • Sale, in February 2023, of the assets related to the Flow Cytometry & Imaging business unit to Cytek® Biosciences. 8
Slide 9: Managerial Outlook on FY 2022 Revenues
MANAGERIAL OUTLOOK ON FY 2022 REVENUES Total FY 2022 Group revenues (data in €/mln) EVOLUTION OF THE BUSINESS IN 2022 Data @CER Data @CUR • Business ex-COVID: +21% @CER, driven by the inclusion of Luminex in the perimeter of consolidation and the good performance of the Immunodiagnostic +10.0% and M
Slide 10: Revenues Growth by Geography and Technology
REVENUES GROWTH BY GEOGRAPHY AND TECHNOLOGY 2022 vs. 2022 vs. BY GEOGRAPHY (change @ CER) BY TECHNOLOGY 2021 2021 NORTH AMERICA EX-COVID IMMUNODIAGNOSTICS EX-COVID • Positive trend of Immunodiagnostic sales mainly driven by the good performance +43.0% REPORTED +8.4% of the U.S. hospital strategy and
Slide 11: FY 2022 Revenues: Managerial Outlook
FY 2022 REVENUES: MANAGERIAL OUTLOOK BY GEOGRAPHY BY TECHNOLOGY Licensed Technologies ex-COVID COVID 15.7% Molecular Diagnostics 17.9% 16.4% North America Rest of the World Direct COVID 15.1% 40.3% 17.9% ex-COVID Immunodiagnostics Europe Direct 50.0% 26.7% 11
Slide 12: FY 2022 Profitability Profile
FY 2022 PROFITABILITY PROFILE (data in €/mln) 43.9% 37.8% 1,361 • The decrease in Adjusted EBITDA* margin is mostly due to lower COVID 1,238 revenues, which had generated significant operating leverage in 2021, only partially offset by the Luminex inclusion in the scope of consolidation. 543 514 FY'
Slide 13: FY 2023 Company Guidance
FY 2023 COMPANY GUIDANCE DiaSorin
Slide 14: FY 2023 Company Guidance
FY 2023 COMPANY GUIDANCE FY 2023 GUIDANCE (@ CER 2022): • TOTAL REVENUES: approx. -14% • REVENUES AT CONSTANT PERIMETER1: approx. -11%, of which: • ex-COVID revenues, net of molecular respiratory business: +4% / + 6% • Molecular respiratory business revenues: approx. -20% • COVID revenues: about € 6
Slide 15: Financial Schemes
/ S < ‘ : xe a Se ~ =S aH; : Wee ofS DiaSorin » \ WYK oN
Slide 16: Income Statement
INCOME STATEMENT FY Change (Amounts in million of euros) 2021 2022 amount % Net Revenues 1,237.7 1,361.1 +123.5 +10.0% Cost of sales (412.9) (460.5) -47.6 +11.5% Gross profit 824.8 900.6 +75.8 +9.2% 66.6% 66.2% -47 bps Sales and marketing expenses (211.3) (292.1) -80.7 +38.2% Research and developmen
Slide 17: Reconciliation to Consolidated Financial Statements
RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in million of Euro) Gross Margin EBITDA EBIT Net Profit IFRS Financial Statements Measures 900.6 497.3 351.3 240.1 % on Revenues 66.2% 36.5% 25.8% 17.6% Adjustments Fair value measurement of the initial Luminex inventory 3.2 3.2 3.2 3.2 “O
Slide 18: Balance Sheet
BALANCE SHEET (Amounts in million of euros) 12/31/2021 12/31/2022 Change Goodwill and intangibles assets 1,943.4 1,995.1 +51.7 Property, plant and equipment 276.2 268.4 -7.7 Other non-current assets 42.6 38.2 -4.4 Net working capital 361.9 434.0 +72.1 Other non-current liabilities (270.2) (309.4) -3
Slide 19: Cash Flow Statement
CASH FLOW STATEMENT FY (Amounts in million of euros) 2021 2022 Cash and cash equivalents at the beginning of the period 339.9 403.0 Cash provided by operating activities 400.7 389.3 Cash used in investing activities (110.4) (232.0) Cash provided/(used) in financing activities 1,273.7 (318.6) Acquisi
Slide 20: Slide 20